Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

The news caused a significant decline in the price of Zeta stock. On November 13, 2024, the price of the company's stock fell 37%, from a closing price of $28.22 per share on November 12, 2024, to $17 ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

A new study from the Tippie College of Business finds that many drug prices actually drop after pharmaceutical company ...

EST Catalyst Pharmaceuticals (CPRX) reports settlement of Firdapse patent litigation with Teva (TEVA) Stay Ahead of the Market:Discover ...

Global Spinal Cord Injury Therapeutics Market is estimated to valued US$ 7.4 billion in 2023 & expected to exhibit CAGR of 5.4% during forecast period 2023-2030 Mr. Shah Coherent Market Insights Pvt.

Argus has recently raised Teva Pharmaceutical Industries Ltd (TEVA) stock to Buy rating, as announced on July 10, 2024, according to Finviz. Earlier, on March 8, 2024, JP Morgan had raised the stock ...

Clinical trials are essential for the development of health care products, and it is increasingly recognized that there is a ...

The complaint alleges nearly two dozen pharmaceutical companies colluded to limit competition, causing costs for certain generic medications to skyrocket.

Gujarat-based drugmaker Intas Pharmaceuticals Ltd., which counts private equity firm ChrysCapital, Singapore state ...

Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Any differences are carefully ...